ClinicalTrials.gg
RecruitingNCT03876054REALITYUpdated Jan 7, 2026

Long-Term Real-World Outcomes Study on Patients Implanted With a Neurostimulator

An observational study in Chronic Pain, sponsored by Abbott Medical Devices. Recruiting at 55 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Abbott Medical Devices (part of Abbott) · Observational

How we know

From the registry’s dates

  • Started Mar 2019; still recruiting 7 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 19 studies in Chronic Pain by Abbott — 2 open to participants now, 2 under way, none of them phase 3. Chronic Pain · Abbott.

Started
2019
with 1 other
Observational
7 of 19
1 open now
Registered
14th of 19
by date

Among the 19 studies in Chronic Pain by Abbott, this one is one of 2 that started in 2019, is one of 7 observational ones, and was the 14th registered.

Chronic Pain

3,228 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

2 of the 19 studies in Chronic Pain by Abbott are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Chronic Pain by Abbott, or all of them as a file.
02

Study summary

The REALITY study is a prospective, post-market, non-randomized, multi-center, single-arm, open-label study intended to collect short- and long-term safety and effectiveness data on various populations implanted with Abbott's neurostimulation systems.

Read the detailed description

This study has broad inclusion criteria and minimal exclusion criteria to ensure the results are representative of the real-world use of these devices. Enrollment caps will be implemented to ensure patients from approved indications are represented. Individuals who are scheduled to receive an implantable Abbott neurostimulation system are eligible for study consideration. The study will enroll up to 2,000 subjects from up to 100 participating centers. Subject enrollment is expected to be completed within 7 years; subjects will be followed for 5 years. The total duration of the study is expected to be 13 years, including enrollment, data collection from all subjects, and study close out.

03

Conditions studied

  • Chronic Pain

Browse trials for

Keywords

  • spinal cord stimulation
  • dorsal root ganglion stimulation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

This clinical investigation will enroll adult male and female individuals scheduled to have an Abbott neurostimulation system implanted. Subjects must meet all eligibility criteria and provide written informed consent prior to conducting any investigation-specific procedures not considered standard of care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must provide written prior to any clinical investigation related procedure.
  2. Subject is at least 18 years (or the minimum age required by local law to consent for participation in a clinical investigation) or older at the time of enrollment.
  3. Subject is scheduled to have an Abbott neurostimulation system implanted within 60 days of baseline.
  4. Subject has a baseline (with no stimulation) pain NRS of ≥ 6.

Exclusion criteria

Exclusion Criteria:

  1. Subject is enrolled, or intends to participate, in a competing clinical study, as determined by Abbott.
  2. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements.
  3. Subject has or is scheduled to receive an intrathecal pump.
  4. Subject is part of a vulnerable population.
  5. Subject has an existing implanted neuromodulation device to address their chronic pain.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Spinal cord stimulation (SCS)

    Subjects using Abbott SCS systems

    Device: Spinal cord stimulation (SCS)

  • Dorsal root ganglion stimulation (DRG)

    Subjects using Abbott DRG system

    Device: Dorsal root ganglion stimulation (DRG)

Interventions

  • DeviceSpinal cord stimulation (SCS)

    Subjects will be implanted with market-released Abbott SCS systems

  • DeviceDorsal root ganglion stimulation (DRG)

    Subjects will be implanted with market-released Abbott DRG system

06

What researchers measure

Primary outcomes

  1. Rate of device and procedure related adverse events, deaths, and device deficiencies

    Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: Baseline

  2. Rate of device and procedure related adverse events, deaths, and device deficiencies

    Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: Permanent Implant Procedure

  3. Rate of device and procedure related adverse events, deaths, and device deficiencies

    Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 6 months

  4. Rate of device and procedure related adverse events, deaths, and device deficiencies

    Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be assessed via Telephone Calls and will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 9 months

  5. Rate of device and procedure related adverse events, deaths, and device deficiencies

    Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 1 Year

  6. Rate of device and procedure related adverse events, deaths, and device deficiencies

    Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be assessed via Telephone Calls and will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 1.5 Years

  7. Rate of device and procedure related adverse events, deaths, and device deficiencies

    Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 2 Years

  8. Rate of device and procedure related adverse events, deaths, and device deficiencies

    Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be assessed via Telephone Calls and will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 2.5 Years

  9. Rate of device and procedure related adverse events, deaths, and device deficiencies

    Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 3 Years

  10. Rate of device and procedure related adverse events, deaths, and device deficiencies

    Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be assessed via Telephone Calls and will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 3.5 Years

  11. Rate of device and procedure related adverse events, deaths, and device deficiencies

    Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 4 Years

  12. Rate of device and procedure related adverse events, deaths, and device deficiencies

    Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be assessed via Telephone Calls and will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 4.5 Years

  13. Rate of device and procedure related adverse events, deaths, and device deficiencies

    Serious adverse device effects (SADEs), adverse device effects (ADEs), deaths, and device deficiencies will be summarized using counts, percentages or Kaplan-Meier survival estimates. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 5 Years

Other outcomes

  1. Mean Change in Clinical improvement from baseline to each follow up visit assessed by PROMIS-29

    The PROMIS-29 is used to estimate overall quality of life by assessing the following domains known to impact activities of daily living: physical function, sleep disturbance, depression, anxiety, fatigue, pain interference, pain intensity, and social role satisfaction. The scale requires subjects to rate the frequency and/or severity of symptoms and experiences related to each of these domains. The final item is an 11-point pain intensity numerical rating scale (NRS) by which the subject rates their average pain over the past 7 days. Subjects should read each item and check the one box that most closely represents their response. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 6 months

  2. Mean Change in Clinical improvement from baseline to each follow up visit assessed by PROMIS-29

    The PROMIS-29 is used to estimate overall quality of life by assessing the following domains known to impact activities of daily living: physical function, sleep disturbance, depression, anxiety, fatigue, pain interference, pain intensity, and social role satisfaction. The scale requires subjects to rate the frequency and/or severity of symptoms and experiences related to each of these domains. The final item is an 11-point pain intensity numerical rating scale (NRS) by which the subject rates their average pain over the past 7 days. Subjects should read each item and check the one box that most closely represents their response. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 1 Year

  3. Mean Change in Clinical improvement from baseline to each follow up visit assessed by PROMIS-29

    The PROMIS-29 is used to estimate overall quality of life by assessing the following domains known to impact activities of daily living: physical function, sleep disturbance, depression, anxiety, fatigue, pain interference, pain intensity, and social role satisfaction. The scale requires subjects to rate the frequency and/or severity of symptoms and experiences related to each of these domains. The final item is an 11-point pain intensity numerical rating scale (NRS) by which the subject rates their average pain over the past 7 days. Subjects should read each item and check the one box that most closely represents their response. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 2 Years

  4. Mean Change in Clinical improvement from baseline to each follow up visit assessed by PROMIS-29

    The PROMIS-29 is used to estimate overall quality of life by assessing the following domains known to impact activities of daily living: physical function, sleep disturbance, depression, anxiety, fatigue, pain interference, pain intensity, and social role satisfaction. The scale requires subjects to rate the frequency and/or severity of symptoms and experiences related to each of these domains. The final item is an 11-point pain intensity numerical rating scale (NRS) by which the subject rates their average pain over the past 7 days. Subjects should read each item and check the one box that most closely represents their response. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 3 Years

  5. Mean Change in Clinical improvement from baseline to each follow up visit assessed by PROMIS-29

    The PROMIS-29 is used to estimate overall quality of life by assessing the following domains known to impact activities of daily living: physical function, sleep disturbance, depression, anxiety, fatigue, pain interference, pain intensity, and social role satisfaction. The scale requires subjects to rate the frequency and/or severity of symptoms and experiences related to each of these domains. The final item is an 11-point pain intensity numerical rating scale (NRS) by which the subject rates their average pain over the past 7 days. Subjects should read each item and check the one box that most closely represents their response. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 4 Years

  6. Mean Change in Clinical improvement from baseline to each follow up visit assessed by PROMIS-29

    The PROMIS-29 is used to estimate overall quality of life by assessing the following domains known to impact activities of daily living: physical function, sleep disturbance, depression, anxiety, fatigue, pain interference, pain intensity, and social role satisfaction. The scale requires subjects to rate the frequency and/or severity of symptoms and experiences related to each of these domains. The final item is an 11-point pain intensity numerical rating scale (NRS) by which the subject rates their average pain over the past 7 days. Subjects should read each item and check the one box that most closely represents their response. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 5 Years

  7. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Numerical Rating Score (NRS)

    The pain NRS consists of 1 question that will be asked by interviewing the subjects. Patients will be asked to rate, from 0 (no pain) to 10 (worst imaginable pain), their pain at the time of study visit specific to the area(s) of chronic pain being treated. A higher score indicates greater pain intensity. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 6 months

  8. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Numerical Rating Score (NRS)

    The pain NRS consists of 1 question that will be asked to the subjects via telephone calls. Patients will be asked to rate, from 0 (no pain) to 10 (worst imaginable pain), their pain at the time of study visit specific to the area(s) of chronic pain being treated. A higher score indicates greater pain intensity. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 9 months

  9. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Numerical Rating Score (NRS)

    The pain NRS consists of 1 question that will be asked by interviewing the subjects. Patients will be asked to rate, from 0 (no pain) to 10 (worst imaginable pain), their pain at the time of study visit specific to the area(s) of chronic pain being treated. A higher score indicates greater pain intensity. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 1 year

  10. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Numerical Rating Score (NRS)

    The pain NRS consists of 1 question that will be asked to the subjects via telephone calls. Patients will be asked to rate, from 0 (no pain) to 10 (worst imaginable pain), their pain at the time of study visit specific to the area(s) of chronic pain being treated. A higher score indicates greater pain intensity. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 1.5 years

  11. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Numerical Rating Score (NRS)

    The pain NRS consists of 1 question that will be asked by interviewing the subjects. Patients will be asked to rate, from 0 (no pain) to 10 (worst imaginable pain), their pain at the time of study visit specific to the area(s) of chronic pain being treated. A higher score indicates greater pain intensity. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 2 Years

  12. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Numerical Rating Score (NRS)

    The pain NRS consists of 1 question that will be asked to the subjects via telephone calls. Patients will be asked to rate, from 0 (no pain) to 10 (worst imaginable pain), their pain at the time of study visit specific to the area(s) of chronic pain being treated. A higher score indicates greater pain intensity. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 2.5 Years

  13. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Numerical Rating Score (NRS)

    The pain NRS consists of 1 question that will be asked by interviewing the subjects. Patients will be asked to rate, from 0 (no pain) to 10 (worst imaginable pain), their pain at the time of study visit specific to the area(s) of chronic pain being treated. A higher score indicates greater pain intensity. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 3 Years

  14. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Numerical Rating Score (NRS)

    The pain NRS consists of 1 question that will be asked to the subjects via telephone calls. Patients will be asked to rate, from 0 (no pain) to 10 (worst imaginable pain), their pain at the time of study visit specific to the area(s) of chronic pain being treated. A higher score indicates greater pain intensity. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 3.5 Years

  15. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Numerical Rating Score (NRS)

    The pain NRS consists of 1 question that will be asked by interviewing the subjects. Patients will be asked to rate, from 0 (no pain) to 10 (worst imaginable pain), their pain at the time of study visit specific to the area(s) of chronic pain being treated. A higher score indicates greater pain intensity. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 4 Years

  16. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Numerical Rating Score (NRS)

    The pain NRS consists of 1 question that will be asked to the subjects via telephone calls. Patients will be asked to rate, from 0 (no pain) to 10 (worst imaginable pain), their pain at the time of study visit specific to the area(s) of chronic pain being treated. A higher score indicates greater pain intensity. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 4.5 Years

  17. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Numerical Rating Score (NRS)

    The pain NRS consists of 1 question that will be asked by interviewing the subjects. Patients will be asked to rate, from 0 (no pain) to 10 (worst imaginable pain), their pain at the time of study visit specific to the area(s) of chronic pain being treated. A higher score indicates greater pain intensity. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 5 Years

  18. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Catastrophizing Scale (PCS)

    Pain Catastrophizing Scale is a validated scale that measures the magnitude of catastrophizing (negative thoughts and feelings while a patient is experiencing pain). Subjects answer questions about how they feel and what they think about when they are in pain (i.e., not at the current moment). The scale includes 13 statements concerning pain experiences that are rated on a scale between 0 'not at all' and 4 'all the time'. The scale is self-administered and takes 5 minutes to complete. A higher score indicates a higher level of catastrophizing. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 6 months

  19. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Catastrophizing Scale (PCS)

    Pain Catastrophizing Scale is a validated scale that measures the magnitude of catastrophizing (negative thoughts and feelings while a patient is experiencing pain). Subjects answer questions about how they feel and what they think about when they are in pain (i.e., not at the current moment). The scale includes 13 statements concerning pain experiences that are rated on a scale between 0 'not at all' and 4 'all the time'. The scale is self-administered and takes 5 minutes to complete. A higher score indicates a higher level of catastrophizing. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 1 Year

  20. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Catastrophizing Scale (PCS)

    Pain Catastrophizing Scale is a validated scale that measures the magnitude of catastrophizing (negative thoughts and feelings while a patient is experiencing pain). Subjects answer questions about how they feel and what they think about when they are in pain (i.e., not at the current moment). The scale includes 13 statements concerning pain experiences that are rated on a scale between 0 'not at all' and 4 'all the time'. The scale is self-administered and takes 5 minutes to complete. A higher score indicates a higher level of catastrophizing. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 2 Years

  21. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Catastrophizing Scale (PCS)

    Pain Catastrophizing Scale is a validated scale that measures the magnitude of catastrophizing (negative thoughts and feelings while a patient is experiencing pain). Subjects answer questions about how they feel and what they think about when they are in pain (i.e., not at the current moment). The scale includes 13 statements concerning pain experiences that are rated on a scale between 0 'not at all' and 4 'all the time'. The scale is self-administered and takes 5 minutes to complete. A higher score indicates a higher level of catastrophizing. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 3 Years

  22. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Catastrophizing Scale (PCS)

    Pain Catastrophizing Scale is a validated scale that measures the magnitude of catastrophizing (negative thoughts and feelings while a patient is experiencing pain). Subjects answer questions about how they feel and what they think about when they are in pain (i.e., not at the current moment). The scale includes 13 statements concerning pain experiences that are rated on a scale between 0 'not at all' and 4 'all the time'. The scale is self-administered and takes 5 minutes to complete. A higher score indicates a higher level of catastrophizing. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 4 Years

  23. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Pain Catastrophizing Scale (PCS)

    Pain Catastrophizing Scale is a validated scale that measures the magnitude of catastrophizing (negative thoughts and feelings while a patient is experiencing pain). Subjects answer questions about how they feel and what they think about when they are in pain (i.e., not at the current moment). The scale includes 13 statements concerning pain experiences that are rated on a scale between 0 'not at all' and 4 'all the time'. The scale is self-administered and takes 5 minutes to complete. A higher score indicates a higher level of catastrophizing. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 5 Years

  24. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Oswestry Disability Index (ODI)

    The ODI is a 10-item scale that evaluates disability related to low-back and leg pain. It is widely used, validated, and has been translated into several languages. Each section in the scale covers a different domain (pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sex life, social life, and traveling). Each item is scored on a scale from 0-5 with the first item scored a "0" and representing no disability. The final item is scored a "5" and represents the maximum level of disability. If more than one response in a section is checked, the highest score is chosen. The scores for each section are summed for a final score ranging from 0 to 50. If an item is not answered, the total score is instead calculated as a percentage of the total possible score for all items that were completed. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 6 months

  25. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Oswestry Disability Index (ODI)

    The ODI is a 10-item scale that evaluates disability related to low-back and leg pain. It is widely used, validated, and has been translated into several languages. Each section in the scale covers a different domain (pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sex life, social life, and traveling). Each item is scored on a scale from 0-5 with the first item scored a "0" and representing no disability. The final item is scored a "5" and represents the maximum level of disability. If more than one response in a section is checked, the highest score is chosen. The scores for each section are summed for a final score ranging from 0 to 50. If an item is not answered, the total score is instead calculated as a percentage of the total possible score for all items that were completed. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 1 Year

  26. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Oswestry Disability Index (ODI)

    The ODI is a 10-item scale that evaluates disability related to low-back and leg pain. It is widely used, validated, and has been translated into several languages. Each section in the scale covers a different domain (pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sex life, social life, and traveling). Each item is scored on a scale from 0-5 with the first item scored a "0" and representing no disability. The final item is scored a "5" and represents the maximum level of disability. If more than one response in a section is checked, the highest score is chosen. The scores for each section are summed for a final score ranging from 0 to 50. If an item is not answered, the total score is instead calculated as a percentage of the total possible score for all items that were completed. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 2 Years

  27. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Oswestry Disability Index (ODI)

    The ODI is a 10-item scale that evaluates disability related to low-back and leg pain. It is widely used, validated, and has been translated into several languages. Each section in the scale covers a different domain (pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sex life, social life, and traveling). Each item is scored on a scale from 0-5 with the first item scored a "0" and representing no disability. The final item is scored a "5" and represents the maximum level of disability. If more than one response in a section is checked, the highest score is chosen. The scores for each section are summed for a final score ranging from 0 to 50. If an item is not answered, the total score is instead calculated as a percentage of the total possible score for all items that were completed. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 3 Years

  28. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Oswestry Disability Index (ODI)

    The ODI is a 10-item scale that evaluates disability related to low-back and leg pain. It is widely used, validated, and has been translated into several languages. Each section in the scale covers a different domain (pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sex life, social life, and traveling). Each item is scored on a scale from 0-5 with the first item scored a "0" and representing no disability. The final item is scored a "5" and represents the maximum level of disability. If more than one response in a section is checked, the highest score is chosen. The scores for each section are summed for a final score ranging from 0 to 50. If an item is not answered, the total score is instead calculated as a percentage of the total possible score for all items that were completed. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 4 Years

  29. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Oswestry Disability Index (ODI)

    The ODI is a 10-item scale that evaluates disability related to low-back and leg pain. It is widely used, validated, and has been translated into several languages. Each section in the scale covers a different domain (pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sex life, social life, and traveling). Each item is scored on a scale from 0-5 with the first item scored a "0" and representing no disability. The final item is scored a "5" and represents the maximum level of disability. If more than one response in a section is checked, the highest score is chosen. The scores for each section are summed for a final score ranging from 0 to 50. If an item is not answered, the total score is instead calculated as a percentage of the total possible score for all items that were completed. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 5 Years

  30. Mean Change in Clinical improvement from baseline to each follow up visit assessed by pain condition-related medication usage

    Pain condition-related medication usage (e.g. opioids, anti-convulsants, anti-depressants, sleep aids, topicals) will be summarized using mean, standard deviation, median, minimum, maximum, and a 95% confidence interval. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 6 months

  31. Mean Change in Clinical improvement from baseline to each follow up visit assessed by pain condition-related medication usage

    Pain condition-related medication usage (e.g. opioids, anti-convulsants, anti-depressants, sleep aids, topicals) will be summarized using mean, standard deviation, median, minimum, maximum, and a 95% confidence interval. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 1 Year

  32. Mean Change in Clinical improvement from baseline to each follow up visit assessed by pain condition-related medication usage

    Pain condition-related medication usage (e.g. opioids, anti-convulsants, anti-depressants, sleep aids, topicals) will be summarized using mean, standard deviation, median, minimum, maximum, and a 95% confidence interval. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 2 Years

  33. Mean Change in Clinical improvement from baseline to each follow up visit assessed by pain condition-related medication usage

    Pain condition-related medication usage (e.g. opioids, anti-convulsants, anti-depressants, sleep aids, topicals) will be summarized using mean, standard deviation, median, minimum, maximum, and a 95% confidence interval. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 3 Years

  34. Mean Change in Clinical improvement from baseline to each follow up visit assessed by pain condition-related medication usage

    Pain condition-related medication usage (e.g. opioids, anti-convulsants, anti-depressants, sleep aids, topicals) will be summarized using mean, standard deviation, median, minimum, maximum, and a 95% confidence interval. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 4 Years

  35. Mean Change in Clinical improvement from baseline to each follow up visit assessed by pain condition-related medication usage

    Pain condition-related medication usage (e.g. opioids, anti-convulsants, anti-depressants, sleep aids, topicals) will be summarized using mean, standard deviation, median, minimum, maximum, and a 95% confidence interval. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 5 Years

  36. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Transcutaneous Oxygen pressure measurement (TcPO2)

    Transcutaneous Oxygen pressure measurement (TcPO2) will be summarized using mean, standard deviation, median, minimum, maximum, and a 95% confidence interval. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 6 months

  37. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Transcutaneous Oxygen pressure measurement (TcPO2)

    Transcutaneous Oxygen pressure measurement (TcPO2) will be summarized using mean, standard deviation, median, minimum, maximum, and a 95% confidence interval. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 1 Year

  38. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Transcutaneous Oxygen pressure measurement (TcPO2)

    Transcutaneous Oxygen pressure measurement (TcPO2) will be summarized using mean, standard deviation, median, minimum, maximum, and a 95% confidence interval. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 2 Years

  39. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Transcutaneous Oxygen pressure measurement (TcPO2)

    Transcutaneous Oxygen pressure measurement (TcPO2) will be summarized using mean, standard deviation, median, minimum, maximum, and a 95% confidence interval. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 3 Years

  40. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Transcutaneous Oxygen pressure measurement (TcPO2)

    Transcutaneous Oxygen pressure measurement (TcPO2) will be summarized using mean, standard deviation, median, minimum, maximum, and a 95% confidence interval. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 4 Years

  41. Mean Change in Clinical improvement from baseline to each follow up visit assessed by Transcutaneous Oxygen pressure measurement (TcPO2)

    Transcutaneous Oxygen pressure measurement (TcPO2) will be summarized using mean, standard deviation, median, minimum, maximum, and a 95% confidence interval. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 5 Years

  42. Rate of patient satisfaction

    Patient satisfaction will be summarized using counts and percentages This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 6 months

  43. Rate of patient satisfaction

    Patient satisfaction will be summarized using counts and percentages This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 1 Year

  44. Rate of patient satisfaction

    Patient satisfaction will be summarized using counts and percentages This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 2 Years

  45. Rate of patient satisfaction

    Patient satisfaction will be summarized using counts and percentages This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 3 Years

  46. Rate of patient satisfaction

    Patient satisfaction will be summarized using counts and percentages This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 4 Years

  47. Rate of patient satisfaction

    Patient satisfaction will be summarized using counts and percentages This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 5 Years

  48. Rate of Patient Global Impression of Change (PGIC) for global improvement of the patient.

    The PGIC is a categorical rating scale used to evaluate the subject's impression of change in his/her condition since the beginning of the study treatment. The subject will be requested to rate their overall change in activity limitations, symptoms, emotions and overall quality of life related to his/her condition on a seven-point categorical scale via an interview technique. The categories are as follows: 1-no change, 2-almost the same, 3-a little better, 4-somewhat better, 5-moderatly better, 6-better, and 7-a great deal better This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 6 months

  49. Rate of Patient Global Impression of Change (PGIC) for global improvement of the patient.

    The PGIC is a categorical rating scale used to evaluate the subject's impression of change in his/her condition since the beginning of the study treatment. The subject will be requested to rate their overall change in activity limitations, symptoms, emotions and overall quality of life related to his/her condition on a seven-point categorical scale via telephone calls. The categories are as follows: 1-no change, 2-almost the same, 3-a little better, 4-somewhat better, 5-moderatly better, 6-better, and 7-a great deal better This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 9 months

  50. Rate of Patient Global Impression of Change (PGIC) for global improvement of the patient.

    The PGIC is a categorical rating scale used to evaluate the subject'simpression of change in his/her condition since the beginning of thestudy treatment. The subject will be requested to rate their overallchange in activity limitations, symptoms, emotions and overall qualityof life related to his/her condition on a seven-point categorical scale via an interview technique. The categories are as follows: 1-nochange, 2-almost the same, 3-a little better, 4-somewhat better, 5-moderatly better, 6-better, and 7-a great deal better. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 1 Year

  51. Rate of Patient Global Impression of Change (PGIC) for global improvement of the patient.

    The PGIC is a categorical rating scale used to evaluate the subject's impression of change in his/her condition since the beginning of the study treatment. The subject will be requested to rate their overall change in activity limitations, symptoms, emotions and overall quality of life related to his/her condition on a seven-point categorical scale via telephone calls. The categories are as follows: 1-no change, 2-almost the same, 3-a little better, 4-somewhat better, 5-moderatly better, 6-better, and 7-a great deal better This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 1.5 Year

  52. Rate of Patient Global Impression of Change (PGIC) for global improvement of the patient.

    The PGIC is a categorical rating scale used to evaluate the subject's impression of change in his/her condition since the beginning of the study treatment. The subject will be requested to rate their overall change in activity limitations, symptoms, emotions and overall quality of life related to his/her condition on a seven-point categorical scale via an interview technique. The categories are as follows: 1-no change, 2-almost the same, 3-a little better, 4-somewhat better, 5-moderatly better, 6-better, and 7-a great deal better. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 2 Years

  53. Rate of Patient Global Impression of Change (PGIC) for global improvement of the patient.

    The PGIC is a categorical rating scale used to evaluate the subject's impression of change in his/her condition since the beginning of the study treatment. The subject will be requested to rate their overall change in activity limitations, symptoms, emotions and overall quality of life related to his/her condition on a seven-point categorical scale via telephone calls. The categories are as follows: 1-no change, 2-almost the same, 3-a little better, 4-somewhat better, 5-moderatly better, 6-better, and 7-a great deal better This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 2.5 Years

  54. Rate of Patient Global Impression of Change (PGIC) for global improvement of the patient.

    The PGIC is a categorical rating scale used to evaluate the subject's impression of change in his/her condition since the beginning of the study treatment. The subject will be requested to rate their overall change in activity limitations, symptoms, emotions and overall quality of life related to his/her condition on a seven-point categorical scale via an interview technique. The categories are as follows: 1-no change, 2-almost the same, 3-a little better, 4-somewhat better, 5-moderatly better, 6-better, and 7-a great deal better. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 3 Years

  55. Rate of Patient Global Impression of Change (PGIC) for global improvement of the patient.

    The PGIC is a categorical rating scale used to evaluate the subject's impression of change in his/her condition since the beginning of the study treatment. The subject will be requested to rate their overall change in activity limitations, symptoms, emotions and overall quality of life related to his/her condition on a seven-point categorical scale via telephone calls. The categories are as follows: 1-no change, 2-almost the same, 3-a little better, 4-somewhat better, 5-moderatly better, 6-better, and 7-a great deal better This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 3.5 Years

  56. Rate of Patient Global Impression of Change (PGIC) for global improvement of the patient.

    The PGIC is a categorical rating scale used to evaluate the subject's impression of change in his/her condition since the beginning of the study treatment. The subject will be requested to rate their overall change in activity limitations, symptoms, emotions and overall quality of life related to his/her condition on a seven-point categorical scale via an interview technique. The categories are as follows: 1-no change, 2-almost the same, 3-a little better, 4-somewhat better, 5-moderatly better, 6-better, and 7-a great deal better. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 4 Years

  57. Rate of Patient Global Impression of Change (PGIC) for global improvement of the patient.

    The PGIC is a categorical rating scale used to evaluate the subject's impression of change in his/her condition since the beginning of the study treatment. The subject will be requested to rate their overall change in activity limitations, symptoms, emotions and overall quality of life related to his/her condition on a seven-point categorical scale via telephone calls. The categories are as follows: 1-no change, 2-almost the same, 3-a little better, 4-somewhat better, 5-moderatly better, 6-better, and 7-a great deal better This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 4.5 Years

  58. Rate of Patient Global Impression of Change (PGIC) for global improvement of the patient.

    The PGIC is a categorical rating scale used to evaluate the subject's impression of change in his/her condition since the beginning of the study treatment. The subject will be requested to rate their overall change in activity limitations, symptoms, emotions and overall quality of life related to his/her condition on a seven-point categorical scale via an interview technique. The categories are as follows: 1-no change, 2-almost the same, 3-a little better, 4-somewhat better, 5-moderatly better, 6-better, and 7-a great deal better. This study has no primary or secondary endpoints, all endpoints are of equal weight.

    Time frame: 5 Years

07

Study locations

1 of 55 sites recruiting
  • Phoenician Centers for Research & Innovation
    Phoenix, Arizona 85021, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Pain Institute of Southern Arizona
    Tucson, Arizona 85718, United States
    Terminated

    Not enrolling at this site — choose another above.

  • California Orthopedics & Spine
    Larkspur, California 94939, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Restore Orthopedics & Spine Center
    Orange, California 92868, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Foothills Pain Management Clinic
    Pomona, California 91767, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Pacific Research Institute
    Santa Rosa, California 95403, United States
    Terminated

    Not enrolling at this site — choose another above.

  • University of Florida Department of Anesthesia
    Gainesville, Florida 32610, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Rush University Medical Center
    Chicago, Illinois 60612, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of Chicago
    Chicago, Illinois 60637, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Goodman Campbell Brain and Spine
    Indianapolis, Indiana 46032, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Nura
    Edina, Minnesota 55435, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Twin Cities Pain Clinic
    Edina, Minnesota 55439, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Mayo Clinic
    Rochester, Minnesota 55905, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Saint Louis Pain Consultants
    Chesterfield, Missouri 63017, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Advanced Pain Care
    Henderson, Nevada 89052, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Nevada Advanced Pain Specialists
    Reno, Nevada 89511, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Ainsworth Institute of Pain Management
    New York, New York 10022, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Unity Spine Center
    Rochester, New York 14626, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The Spine & Pain Institute of New York
    Staten Island, New York 10305, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Premier Pain Solutions
    Asheville, North Carolina 28803, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Adena Bone and Joint Center
    Chillicothe, Ohio 45601, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Premier Pain Treatment Institute
    Loveland, Ohio 45140, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Pacific Sports & Spine
    Eugene, Oregon 97401, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Spinal Diagnostics
    Tualatin, Oregon 97062, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Center for Interventional Pain & Spine
    Exton, Pennsylvania 19341, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Expert Pain
    Houston, Texas 77079, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Central Texas Pain Institute
    Killeen, Texas 76542, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Integrated Pain Associates
    Killeen, Texas 76542, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Advanced Pain Care
    Round Rock, Texas 78664, United States
    Terminated

    Not enrolling at this site — choose another above.

  • The Spine & Nerve Center of St Francis Hospital
    Charleston, West Virginia 25301, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Metro Pain Group
    Clayton, Victoria 3168, Australia
    Terminated

    Not enrolling at this site — choose another above.

  • Precision Brain, Spine & Pain Centre
    Kew, Victoria 3101, Australia
    Terminated

    Not enrolling at this site — choose another above.

  • AZ Nikolaas
    Sint-Niklaas, Eflndrs 9100, Belgium
    Terminated

    Not enrolling at this site — choose another above.

  • AZ Delta vzw
    Roeselare, West Flanders 8800, Belgium
    Terminated

    Not enrolling at this site — choose another above.

  • Universitäts Klinikum Tübingen
    Tübingen, Bad-wur 72076, Germany
    Terminated

    Not enrolling at this site — choose another above.

  • Klinikum Ingolstadt GmbH
    Ingolstadt, Bavaria 85049, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Krankenhaus Porz am Rhein
    Cologne, Koln 51149, Germany
    Recruiting
    • Thomas May · Principal investigator
  • Klinikum Duisburg GmbH
    Duisburg, N. RHIN 47055, Germany
    Terminated

    Not enrolling at this site — choose another above.

  • Universitaetsklinikum Duesseldorf
    Düsseldorf, N. RHIN 40225, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Krankenhaus Neuwerk Maria von den Aposteln
    Mönchengladbach, N. RHIN 41066, Germany
    Terminated

    Not enrolling at this site — choose another above.

  • Kliniken der Stadt Köln-Merheim
    Cologne, North Rhine-Westphalia 51109, Germany
    Terminated

    Not enrolling at this site — choose another above.

  • Universitätsklinikum Schleswig-Holstein
    Lübeck, Schleswig-Holstein 23538, Germany
    Terminated

    Not enrolling at this site — choose another above.

  • Hospital Gera -Zentrum für interdisziplinäre Schmerztherapie
    Gera, Thuringia 07548, Germany
    Terminated

    Not enrolling at this site — choose another above.

  • Azienda Ospedaliera Monaldi
    Naples, Campani 80131, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fondazione Salvatore Maugeri
    Pavia, Lombard 27100, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Erasmus MC
    Rotterdam, S Holln 3015, Netherlands
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • St. Antonius Ziekenhuis
    Nieuwegein, Utrecht 3435 CM, Netherlands
    Terminated

    Not enrolling at this site — choose another above.

  • Hospital Universitario de Salamanca
    Salamanca, Cstleon 37007, Spain
    Terminated

    Not enrolling at this site — choose another above.

  • Hospital Universitario Puerta de Hierro
    Majadahonda, Madrid 28222, Spain
    Terminated

    Not enrolling at this site — choose another above.

  • Hospital Universitari i Politècnic La Fe
    Valencia, Valencia 46026, Spain
    Terminated

    Not enrolling at this site — choose another above.

  • Hôpital du Valais
    Sion, Valais 1951, Switzerland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Norfolk and Norwich Hospital
    Norwich, England NR4 7UY, United Kingdom
    Terminated

    Not enrolling at this site — choose another above.

  • The Walton Centre
    Liverpool, North West England L9 7LJ, United Kingdom
    Terminated

    Not enrolling at this site — choose another above.

  • Southmead Hospital
    Bristol, Sowest BS10 5NB, United Kingdom
    Terminated

    Not enrolling at this site — choose another above.

  • Seacroft Hospital
    Leeds, Yorkshire and the Humber LS14 6UH, United Kingdom
    Terminated

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2019 (actual). Primary completion is estimated for Jun 2029, 123 months after the start.

Of 363 observational studies under Chronic Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 56. This study's planned 123 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2019
First posted
Mar 15, 2019
StartActual
Mar 13, 2019
Primary completionEst.
Jun 2029
CompletionEst.
Dec 2029
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03876054
Responsible party
Sponsor
First posted
Mar 15, 2019
Start date
Mar 13, 2019
Primary completion
Jun 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Jan 7, 2026

Study contacts

Bram Blomme
Contact
bram.blomme@abbott.com
+32 474 74 83 10
Sonar Pradhan
Contact
sonar.pradhan@abbott.com
+1 818-282-6456
Devyani Nanduri
study director · Abbott Medical Devices Neuromodulation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion